Table 1.
Drug Class | Representatives (Drug Groups or Drugs) | Mechanism of Action | Drug Target | Mechanisms of AMR |
---|---|---|---|---|
Mechanism of action | ||||
Inhibition of cell wall synthesis | ||||
β lactams | Penicillins Cephalosporins Carbapenems Monobactams |
Inhibition of cell wall synthesis | Peptidoglycan biosynthesis | Drug uptake limitation (decreased number of pores or changed selectivity of porins, no outer cell membrane) Enzymatic drug inactivation by hydrolysis (β lactamase production) RND 1 efflux pumps (reduction of drug absorption in the cell) Altered targets (PBP 2 alteration in gram-positive bacteria) |
Glycopeptides | Vancomycin Teicoplanin |
Peptidoglycan biosynthesis | Drug uptake limitation (thickened cell wall due to mutation, no outer cell wall or impermeable outer membrane in gram-negative bacteria) Altered targets (reprogramming of peptidoglycan biosynthesis via mutation of D-Ala-D-Ala ligase and peptidoglycan modification) |
|
Disruption of bacterial cell inner membrane | ||||
Lipopeptides | Daptomycin | Disruption of bacterial cell inner membrane | Inner membrane | Enzymatic drug inactivation by immobilization a hydrolytic cleavage of the ester bond between the threonine and kynurenine residue Altered targets (genetically determined alteration of the cell surface charge leading to the repulsion of the anionic daptomycin molecules, changes in the membrane composition via the alteration of phospholipid membrane metabolism, alteration of complex transcriptional regulatory networks governing the cell envelope stress response and membrane homeostasis, indirectly affected cell wall synthesis and consequently—thickness |
Disruption of cell membranes’ structure, primarily the outer membrane, that finally causes cell lysis | ||||
Cationic peptides | Colistin Polymyxin E |
Disruption of cell membranes’ structure, primarily the outer membrane, that finally causes cell lysis 1 | Cell membranes | Altered targets (overproduction of capsular polysaccharide, loss of LPSs 3 from bacterial outer membrane, modification of lipid A-pEtN 4 SMR 5 efflux pumps (reduction of drug absorption in the cell) |
Aminoglycosides | Streptomycin Gentamicin Kanamycin Amikacin Tobramycin Spectinomycin |
Inhibition of cytoplasm protein synthesis | Translation | Drug uptake limitation (cell wall polarity) Enzymatic drug inactivation (phosphorylation, acetylation, nucleotydilation) RND efflux pumps (reduction of drug absorption in the cell) Altered targets (ribosomal alteration due to mutation in 16S rRNA gene, methylation by the 16S ribosomal methylases) |
Tetracyclines | Tetracycline Doxycycline Minocycline Tigecycline |
Translation | Drug uptake limitation (decreased number of pores) Enzymatic drug inactivation (hydroxylation under FAD 6-dependent monooxygenases TetX 7 and TetX2 8) Efflux pumps (reduction of drug absorption in the cell) Altered targets (ribosomal protection) |
|
Macrolides | Erythromycin Azithromycin Clarithromycin |
Translation | Enzymatic drug inactivation (hydrolysis, glycosylation, phosphorylation) ABC 9, MFS 10, RND efflux pumps (reduction of drug absorption in the cell) Altered targets (ribosomal mutation, 23S rRNA methylation, ribosomal protection by ABC 11 proteins) |
|
Lincosamides | Clindamycin | Translation | Altered targets (ribosomal methylation due to modification of 23S rRNA by methyltransferases in gram-positive bacteria) ABC, RND efflux pumps (reduction of drug absorption in the cell) Enzymatic drug inactivation (phosphorylation, nucleotidylation) |
|
Amphenicols | Chloramphenicol | Translation | Enzymatic drug inactivation (acetylation) MFS, RND efflux pumps (reduction of drug absorption in the cell) Altered targets (ribosomal methylation due to mutations within 23S rRNA of the 50S ribosomal subunit) |
|
Streptogramins | Quinupristin and dalfopristin | Translation | Altered target (ribosomal alteration due to mutation of 23S rRNA in 50S ribosomal subunit) ABC efflux pumps (reduction of drug absorption in the cell) Enzymatic dug inactivation (acetylation, breakage of a carbo-oxygen bond by carbon-oxygen lyase) |
|
Oxazolidinones | Linezolid | Translation | Altered target (ribosomal methylation by methyltransferases via modification of the 23S rRNA, ribosomal protection by ABC proteins) RND efflux pumps (reduction of drug absorption in the cell) |
|
Fluoroquinolones | Ciprofloxacin Ofloxacin Levofloxacin |
Inhibition of nucleic acid synthesis | DNA replication | Enzymatic drug inactivation (acetylation) MATE 12, MFS, RND efflux pumps (reduction of drug absorption in the cell) Altered targets (DNA gyrase modification in gram-negative bacteria, topoisomerase IV modification—in gram-positive, protection of DNA gyrase and topoisomerase IV) |
Rifamycins | Rifampin | RNA synthesis | Altered targets (mutation of rpoB gene which encodes the β subunit of RNA polymerase) RND, SMR efflux pumps (reduction of drug absorption in the cell) |
|
Pyrimidines | Trimethoprim | Inhibition of metabolic pathways (folic acid metabolism) | DHFR 13 | RND efflux pumps (reduction of drug absorption in the cell) Altered targets (reduced binding and overproduction of DHFR due to modification or acquisition of novel DHFR genes) |
Sulfonamides | Sulfamethoxazole | DHPS 14 | RND efflux pumps (reduction of drug absorption in the cell) Altered targets (DHPS reduce d binding, overproduction of resistant DHPS due to mutations in the DHPS gene and sul1/2 genes, which encode distinct DHPSs that are less susceptible to sulphonamide |
1 RND—Resistance Nodulation and Cell Division Superfamily, 2 PBP—Penicillin binding proteins, 3 LPSs—lipopolysaccharides, 4 lipid A-pEtN—Lipid A phosphoethanolamine transferase, 5 SMR—Small Multidrug Resistance Superfamily, 6 FAD—Flavin adenine dinucleotide, 7 TetX—Monooxygenase conferring resistance to tetracycline antibiotics, 8 TetX2—Monooxygenase conferring resistance to tetracycline and tigecycline, 9 ABC—Adenosine triphosphate-binding cassette Superfamily of transmembrane transporters, 10 MFS—Major Facilitator Superfamily, 11 ABC proteins—Members of adenosine triphosphate-binding cassette F proteins, 12 MATE—Multidrug and Toxic Compound Extrusion Superfamily, 13 DHFR—Dihydrofolate reductase, 14 DHPS—Dihydropteroate synthase.